Cancer Type-specific Adverse Events of Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis

Overview

Journal Heliyon

Date 2025 Jan 27

PMID 39866435

Authors

Xuhui Tong

Rong Tang

Jin Xu

Wei Wang

Qiong Du

Si Shi

Xianjun Yu

Affiliations

Soon will be listed here.

Abstract

Background: The distribution of adverse events (AEs) triggered by immune checkpoint inhibitors (ICIs) across different cancer types has never been demonstrated.

Methods: Randomised controlled trials exclusively assessing ICI monotherapy in cohorts of over 100 patients were considered. Our primary outcome was a comprehensive summary of the distribution of all-grade treatment-related adverse events (TRAEs) as well as serious TRAEs (CTCAE grade 3 or higher) across different malignancies. The study is registered with PROSPERO CRD42023387934.

Findings: 75 trials that enrolled over 100 patients were included. While investigating the incidence of each TRAE across various cancers, we found special linkages existed between certain TRAEs and particular cancer types. In anti-PD-1 monotherapy group, melanoma patients experienced the most frequent fatigue (31.1 %, 95 % CI 29.7%-32.5 %); the incidences of severe pneumonitis and other respiratory disorders were highest in Hodgkin lymphoma (4.1 %, 95 % CI 1.5%-8.6 %; 4.1 %, 95 % CI 1.5%-8.6 %, respectively). Among individuals undergoing single-agent anti-PD-L1, higher frequency of all-grade pruritus occurred in 19.0 % of renal cell carcinoma (RCC) patients (95 % CI 15.2%-23.2 %), and the highest probability of developing other severe musculoskeletal disorders was observed in patients with RCC (6.2 %, 95 % CI 4.0%-9.0 %). In anti-CTLA-4 monotherapy, the incidences of both all-grade and severe diarrhea occurred most frequently in prostate cancer patients (41.9 %, 95 % CI 37.9%-47.9; 14.8 %, 95 % CI 11.5%-18.7 %, respectively).

Interpretation: This is the first comprehensive study addressing the distribution of various TRAEs across cancer types. Our research emphasizes the significance of considering cancer-specific TRAEs when using ICIs for treatment.

References

Sonpavde G, Grivas P, Lin Y, Hennessy D, Hunt J . Immune-related adverse events with PD-1 versus PD-L1 inhibitors: a meta-analysis of 8730 patients from clinical trials. Future Oncol. 2021; 17(19):2545-2558. DOI: 10.2217/fon-2020-1222. View

Moser E, Noordijk E, van Leeuwen F, le Cessie S, Baars J, Thomas J . Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphoma. Blood. 2005; 107(7):2912-9. DOI: 10.1182/blood-2005-08-3392. View

Martins F, Sofiya L, Sykiotis G, Lamine F, Maillard M, Fraga M . Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol. 2019; 16(9):563-580. DOI: 10.1038/s41571-019-0218-0. View

Burke K, Grebinoski S, Sharpe A, Vignali D . Understanding adverse events of immunotherapy: A mechanistic perspective. J Exp Med. 2021; 218(1). PMC: 7754677. DOI: 10.1084/jem.20192179. View

Wolchok J, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob J, Cowey C . Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med. 2017; 377(14):1345-1356. PMC: 5706778. DOI: 10.1056/NEJMoa1709684. View

Byrne K, Turk M . New perspectives on the role of vitiligo in immune responses to melanoma. Oncotarget. 2011; 2(9):684-94. PMC: 3248219. DOI: 10.18632/oncotarget.323. View

Berner F, Bomze D, Lichtensteiger C, Walter V, Niederer R, Ali O . Autoreactive napsin A-specific T cells are enriched in lung tumors and inflammatory lung lesions during immune checkpoint blockade. Sci Immunol. 2022; 7(75):eabn9644. DOI: 10.1126/sciimmunol.abn9644. View

Vanhersecke L, Brunet M, Guegan J, Rey C, Bougouin A, Cousin S . Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression. Nat Cancer. 2022; 2(8):794-802. PMC: 8809887. DOI: 10.1038/s43018-021-00232-6. View

Myrehaug S, Pintilie M, Yun L, Crump M, Tsang R, Meyer R . A population-based study of cardiac morbidity among Hodgkin lymphoma patients with preexisting heart disease. Blood. 2010; 116(13):2237-40. DOI: 10.1182/blood-2010-01-263764. View

10.

Palermo B, Campanelli R, Garbelli S, Mantovani S, Lantelme E, Brazzelli V . Specific cytotoxic T lymphocyte responses against Melan-A/MART1, tyrosinase and gp100 in vitiligo by the use of major histocompatibility complex/peptide tetramers: the role of cellular immunity in the etiopathogenesis of vitiligo. J Invest Dermatol. 2001; 117(2):326-32. DOI: 10.1046/j.1523-1747.2001.01408.x. View

11.

de Vries S, Schaapveld M, Janus C, Daniels L, Petersen E, van der Maazen R . Long-Term Cause-Specific Mortality in Hodgkin Lymphoma Patients. J Natl Cancer Inst. 2020; 113(6):760-769. PMC: 8168246. DOI: 10.1093/jnci/djaa194. View

12.

Shoushtari A, Friedman C, Navid-Azarbaijani P, Postow M, Callahan M, Momtaz P . Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma. JAMA Oncol. 2017; 4(1):98-101. PMC: 5833656. DOI: 10.1001/jamaoncol.2017.2391. View

13.

Wu Z, Chen Q, Qu L, Li M, Wang L, Mir M . Adverse Events of Immune Checkpoint Inhibitors Therapy for Urologic Cancer Patients in Clinical Trials: A Collaborative Systematic Review and Meta-analysis. Eur Urol. 2022; 81(4):414-425. DOI: 10.1016/j.eururo.2022.01.028. View

14.

Pesonen S, Diaconu I, Kangasniemi L, Ranki T, Kanerva A, Pesonen S . Oncolytic immunotherapy of advanced solid tumors with a CD40L-expressing replicating adenovirus: assessment of safety and immunologic responses in patients. Cancer Res. 2012; 72(7):1621-31. DOI: 10.1158/0008-5472.CAN-11-3001. View

15.

Wang Y, Zhou S, Yang F, Qi X, Wang X, Guan X . Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis. JAMA Oncol. 2019; 5(7):1008-1019. PMC: 6487913. DOI: 10.1001/jamaoncol.2019.0393. View

16.

Dougan M, Luoma A, Dougan S, Wucherpfennig K . Understanding and treating the inflammatory adverse events of cancer immunotherapy. Cell. 2021; 184(6):1575-1588. PMC: 7979511. DOI: 10.1016/j.cell.2021.02.011. View

17.

Okiyama N, Tanaka R . Immune-related adverse events in various organs caused by immune checkpoint inhibitors. Allergol Int. 2022; 71(2):169-178. DOI: 10.1016/j.alit.2022.01.001. View

18.

Lyon A, Yousaf N, Battisti N, Moslehi J, Larkin J . Immune checkpoint inhibitors and cardiovascular toxicity. Lancet Oncol. 2018; 19(9):e447-e458. DOI: 10.1016/S1470-2045(18)30457-1. View

19.

Xu C, Chen Y, Du X, Liu J, Huang C, Chen L . Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis. BMJ. 2018; 363:k4226. PMC: 6222274. DOI: 10.1136/bmj.k4226. View

20.

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. PMC: 8005924. DOI: 10.1136/bmj.n71. View